BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 34769149)

  • 21. Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition.
    Reiff T; Huber L; Kramer M; Delattre O; Janoueix-Lerosey I; Rohrer H
    Development; 2011 Nov; 138(21):4699-708. PubMed ID: 21989914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration.
    Huang H; Gont A; Kee L; Dries R; Pfeifer K; Sharma B; Debruyne DN; Harlow M; Sengupta S; Guan J; Yeung CM; Wang W; Hallberg B; Palmer RH; Irwin MS; George RE
    Cell Rep; 2021 Jul; 36(2):109363. PubMed ID: 34260934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cells.
    Fadeev A; Mendoza-Garcia P; Irion U; Guan J; Pfeifer K; Wiessner S; Serluca F; Singh AP; Nüsslein-Volhard C; Palmer RH
    Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E630-E638. PubMed ID: 29317532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroblastoma: When differentiation goes awry.
    Zeineldin M; Patel AG; Dyer MA
    Neuron; 2022 Sep; 110(18):2916-2928. PubMed ID: 35985323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogenic mutations of ALK in neuroblastoma.
    Ogawa S; Takita J; Sanada M; Hayashi Y
    Cancer Sci; 2011 Feb; 102(2):302-8. PubMed ID: 21205076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma.
    Siaw JT; Javanmardi N; Van den Eynden J; Lind DE; Fransson S; Martinez-Monleon A; Djos A; Sjöberg RM; Östensson M; Carén H; Trøen G; Beiske K; Berbegall AP; Noguera R; Lai WY; Kogner P; Palmer RH; Hallberg B; Martinsson T
    Cell Rep; 2020 Sep; 32(12):108171. PubMed ID: 32966799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conformational Transition of Key Structural Features Involved in Activation of ALK Induced by Two Neuroblastoma Mutations and ATP Binding: Insight from Accelerated Molecular Dynamics Simulations.
    He MY; Li WK; Zheng QC; Zhang HX
    ACS Chem Neurosci; 2018 Jul; 9(7):1783-1792. PubMed ID: 29638111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines.
    Del Grosso F; De Mariano M; Passoni L; Luksch R; Tonini GP; Longo L
    BMC Cancer; 2011 Dec; 11():525. PubMed ID: 22192458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of the Neuroblastoma-Associated ALK-F1174L Activating Mutation During Embryogenesis Impairs the Differentiation of Neural Crest Progenitors in Sympathetic Ganglia.
    Vivancos Stalin L; Gualandi M; Schulte JH; Renella R; Shakhova O; Mühlethaler-Mottet A
    Front Oncol; 2019; 9():275. PubMed ID: 31058082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
    Fischer M; Moreno L; Ziegler DS; Marshall LV; Zwaan CM; Irwin MS; Casanova M; Sabado C; Wulff B; Stegert M; Wang L; Hurtado FK; Branle F; Geoerger B; Schulte JH
    Lancet Oncol; 2021 Dec; 22(12):1764-1776. PubMed ID: 34780709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
    Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH
    EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD44-high neural crest stem-like cells are associated with tumour aggressiveness and poor survival in neuroblastoma tumours.
    Vega FM; Colmenero-Repiso A; Gómez-Muñoz MA; Rodríguez-Prieto I; Aguilar-Morante D; Ramírez G; Márquez C; Cabello R; Pardal R
    EBioMedicine; 2019 Nov; 49():82-95. PubMed ID: 31685444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells.
    Bergaggio E; Tai WT; Aroldi A; Mecca C; Landoni E; Nüesch M; Mota I; Metovic J; Molinaro L; Ma L; Alvarado D; Ambrogio C; Voena C; Blasco RB; Li T; Klein D; Irvine DJ; Papotti M; Savoldo B; Dotti G; Chiarle R
    Cancer Cell; 2023 Dec; 41(12):2100-2116.e10. PubMed ID: 38039964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.
    Bachetti T; Di Paolo D; Di Lascio S; Mirisola V; Brignole C; Bellotti M; Caffa I; Ferraris C; Fiore M; Fornasari D; Chiarle R; Borghini S; Pfeffer U; Ponzoni M; Ceccherini I; Perri P
    PLoS One; 2010 Oct; 5(10):. PubMed ID: 20957039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
    Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
    Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.
    Lopez-Delisle L; Pierre-Eugène C; Louis-Brennetot C; Surdez D; Raynal V; Baulande S; Boeva V; Grossetête-Lalami S; Combaret V; Peuchmaur M; Delattre O; Janoueix-Lerosey I
    Oncogene; 2018 Mar; 37(11):1417-1429. PubMed ID: 29321660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promising therapeutic targets in neuroblastoma.
    Matthay KK; George RE; Yu AL
    Clin Cancer Res; 2012 May; 18(10):2740-53. PubMed ID: 22589483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of ALK as a major familial neuroblastoma predisposition gene.
    Mossé YP; Laudenslager M; Longo L; Cole KA; Wood A; Attiyeh EF; Laquaglia MJ; Sennett R; Lynch JE; Perri P; Laureys G; Speleman F; Kim C; Hou C; Hakonarson H; Torkamani A; Schork NJ; Brodeur GM; Tonini GP; Rappaport E; Devoto M; Maris JM
    Nature; 2008 Oct; 455(7215):930-5. PubMed ID: 18724359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
    Guan J; Fransson S; Siaw JT; Treis D; Van den Eynden J; Chand D; Umapathy G; Ruuth K; Svenberg P; Wessman S; Shamikh A; Jacobsson H; Gordon L; Stenman J; Svensson PJ; Hansson M; Larsson E; Martinsson T; Palmer RH; Kogner P; Hallberg B
    Cold Spring Harb Mol Case Stud; 2018 Aug; 4(4):. PubMed ID: 29907598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.